Xinnate (private company)

See something wrong or missing? Let us know
Offices:Lund
Business model:B2B

Xinnate is a pharmaceutical development company in Lund, Sweden developing novel, pharmaceutical therapies based on a pioneering technology of immune modulating peptides, that targets dysfunctional healing by controlling presence of microbials and the complex interplay of inflammatory responses.

Investors: we tracked 1 investor

You need an account to access this feature. Log in or create one from here.

Do you have a question? Talk to us.

values in USD

Investments 12.99M


You need an account to access this feature. Log in or create one from here.

Do you have a question? Talk to us.

Companies with similar profile to Xinnate

Name Criteria
France AbolerIS Pharma
60%
  • Similar verticals: Biotech, Health services, Pharma
  • Similar business models: B2B
  • At least one other investor: found 1
  • Total raised in a similar range: 10M+ USD
Denmark Acesion Pharma
60%
  • Similar verticals: Biotech, Health services, Pharma
  • Similar business models: B2B
  • At least one other investor: found 1
  • Total raised in a similar range: 10M+ USD
Sweden Cinclus Pharma
60%
  • Similar verticals: Biotech, Health services, Pharma
  • Similar business models: B2B
  • At least one other investor: found 1
  • Total raised in a similar range: 10M+ USD
Finland DelSiTech
60%
  • Similar verticals: Biotech, Health services, Pharma
  • Similar business models: B2B
  • At least one other investor: found 1
  • Total raised in a similar range: 10M+ USD
Sweden iCellate
60%
  • Similar verticals: Biotech, Health services, Pharma
  • Similar business models: B2B
  • At least one other investor: found 1
  • Total raised in a similar range: 10M+ USD
Finland Nanoform Finland
60%
  • Similar verticals: Biotech, Health services, Pharma
  • Similar business models: B2B
  • At least one other investor: found 1
  • Total raised in a similar range: 10M+ USD
Denmark NMD Pharma
60%
  • Similar verticals: Biotech, Health services, Pharma
  • Similar business models: B2B
  • At least one other investor: found 1
  • Total raised in a similar range: 10M+ USD
Spain Oncomatryx
60%
  • Similar verticals: Biotech, Health services, Pharma
  • Similar business models: B2B
  • At least one other investor: found 1
  • Total raised in a similar range: 10M+ USD
France Owkin
60%
  • Similar verticals: Biotech, Health services, Pharma
  • Similar business models: B2B
  • At least one other investor: found 1
  • Total raised in a similar range: 10M+ USD
Switzerland Pharvaris
60%
  • Similar verticals: Biotech, Health services, Pharma
  • Similar business models: B2B
  • At least one other investor: found 1
  • Total raised in a similar range: 10M+ USD
Top